Taisho Pharmaceutical Co., Ltd.
π―π΅Japan
A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis
Phase 3
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Taisho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT06745531
- Locations
- π―π΅
Taisho Pharmaceutical Co., Ltd selected site, Tokyo, Japan
A Phase 2 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis with Phosphate Binders
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Taisho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT06745518
- Locations
- π―π΅
Taisho Pharmaceutical Co., Ltd selected site, Tokyo, Japan
A Mass Balance Study of TS-172 in Healthy Adult Subjects
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Taisho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT06596356
- Locations
- π―π΅
Taisho Pharmaceutical Co., Ltd selected site, Tokyo, Japan
A Study to Investigate the Next-day Residual Effects of TS-142 in Healthy Elderly Subjects
- First Posted Date
- 2023-04-19
- Last Posted Date
- 2023-09-05
- Lead Sponsor
- Taisho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 43
- Registration Number
- NCT05819710
- Locations
- π―π΅
Taisho Pharmaceutical Co., Ltd selected site, Tokyo, Japan
A Food Effect Study of TS-142 in Healthy Subjects
- First Posted Date
- 2023-02-01
- Last Posted Date
- 2023-04-07
- Lead Sponsor
- Taisho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT05707897
- Locations
- π―π΅
Taisho Pharmaceutical Co., Ltd selected site, Tokyo, Japan
A Phase 2 Dose-finding Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Taisho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 326
- Registration Number
- NCT05699239
- Locations
- π―π΅
Taisho Pharmaceutical Co., Ltd selected site, Tokyo, Japan
A Pharmacokinetic Study of TS-142 in Patients With Hepatic Impairment
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-11-22
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- Taisho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 84
- Registration Number
- NCT05624944
- Locations
- π―π΅
Taisho Pharmaceutical Co., Ltd selected site, Tokyo, Japan
Long-Term Study of TS-142 in Patients With Insomnia
- First Posted Date
- 2022-07-18
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Taisho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 401
- Registration Number
- NCT05461352
- Locations
- π―π΅
Taisho Pharmaceutical Co., Ltd selected site, Tokyo, Japan
Phase III Study of TS-142 in Patients With Insomnia
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-07-12
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- Taisho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 1155
- Registration Number
- NCT05453136
- Locations
- π―π΅
Taisho Pharmaceutical Co., Ltd selected site, Tokyo, Japan
A Phase I Study of TS-172 in Healthy Adult Subjects (Single and Multiple Doses)
- First Posted Date
- 2021-07-28
- Last Posted Date
- 2022-10-06
- Lead Sponsor
- Taisho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 41
- Registration Number
- NCT04979572
- Locations
- π―π΅
Taisho Pharmaceutical Co., Ltd selected site, Toshima-ku, Japan
Β© Copyright 2024. All Rights Reserved by MedPath